石药集团:JMT202(重组全人源抗βKLOTHO单克隆抗体)获美国临床试验批准

格隆汇资讯
02 May

格隆汇5月2日丨石药集团(01093.HK)公告,集团开发的重组全人源抗β Klotho单克隆抗体药物JMT202已获美国食品药品监督管理局(FDA)批准,可以在美国开展临床研究。该产品亦已于2024年5月获得中国国家药品监督管理局批准,目前正在中国开展临床试验。该产品为FGFR1c/β Klotho受体激动剂,通过结合β Klotho蛋白,特异性地激活FGFR1c/β Klotho受体复合物,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10